Business Wire

FL-KNOWBE4

1.12.2021 14:02:14 CET | Business Wire | Press release

Share
KnowBe4’s Team of Cybersecurity Experts Release Predictions for 2022

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced its 2022 cybersecurity predictions from its team of industry experts.

The predicted cybersecurity trends for 2022 include:

  • Nuclear Ransomware 3.0
    A trend that is currently building for the future on the side of the bad actor is that ransomware gangs are morphing into "everything gangs." Instead of just doing ransomware and data exfiltration, they are doing cryptomining, botnet creation, DDoS attacks, etc. The attack gangs of the future will look at every new victim as a pot of gold and try to figure out what to do and in which order to maximize financial value extraction.
  • New Malware Family: Not the Kind You Would Welcome Into Your Home
    A new dangerous and persistent metamorphic malware family called “Tardigrade” is a new strain of Windows malware. It can constantly adapt to avoid detection and was first found targeting the biotech industry, including the infrastructure behind vaccine manufacturing, according to security researchers. This “metamorphic” ability prevents the malware from leaving a consistent signature behind, making it very hard for antivirus programs to spot. It contains the sneaky ability to spread both via phishing emails and USB devices.
  • Virtually Pwned
    Meta, the brand formerly known as Facebook, will entice masses to join the Metaverse. This will spawn a rush to establish dominance in the virtual world. As a result, hackers will also be drawn into this world, and we will see virtual attacks against both individuals and organizations. We will see an explosion of bad things happen to people and resources in the virtual world…virtual looting, virtual theft, account takeovers and more creative criminal exploits.
  • Disinformation Powered by Deep Fakes Will Cause a Political/Financial Circus
    We will see a coordinated disinformation campaign that will rely heavily on deep fakes and manipulated footage to cause a political/financial circus. A deep fake could be used to manipulate a certain political party’s views by stating false opinions, promises or beliefs of a particular candidate. This could cause a chain reaction of certain organizations pulling funds from a political campaign based on statements made by the deep fake.
  • An Attack Against Cryptocurrency Will Hit Real World Economies
    A major cryptocurrency will be attacked, causing billions of dollars in lost value either through direct theft or in value loss. Many individuals and organizations will be severely impacted and it will be referred to as the Black Crypto Day.
  • A Major EU Power Station/Utility Provider Will Be Crippled in a Novel Way Other Than Ransomware
    Most likely somewhere in Eastern Europe, we will see some bad actors cut off your power, your gas and your water. Then as you watch in horror as your phone, tablets and laptop batteries die, they will hand out an olive branch that many will be ready to accept, but at what cost?
  • Someone Will Hack Back the Wrong Bad Actor and Trigger an International Incident
    An overly-eager security researcher will think they have identified the culprit behind a major attack. In an act of retaliation, they will hack back only to discover they did not attribute the attack correctly. This will cause a major international incident and the organization responsible will be placed under extreme scrutiny.
  • The Rise of Dark Economy M&A
    A lot of criminal gangs have become extremely wealthy. In fact, some shady organizations are large enough to be listed on a stock exchange. So, we will see a more formalized dark economy emerge with some M&A activity taking place as some gangs will look to cash-in by selling their organization while others look to grow in capability and reach.
  • When AI Goes Wrong In 2022
    We’ll see the first wave of intelligent attack bots. The future is good threat hunting bots versus bad bots and the best algorithm wins.

“In many ways, it seems as if things are getting worse for cybersecurity professionals who are trying their best to protect their organizations,” said Stu Sjouwerman, CEO, KnowBe4. “But I think we are starting to see more of a focus on the human element, including human behavior, of cybersecurity protection measures. This is a positive shift in direction because people can implement all of the technical tools and controls in the world, but if they do not focus their efforts on the human layer of security, they are going to run into challenges. At the end of the day, a strong security culture is what truly matters and what we will see organizations focused on as we move into 2022.”

The predicted trends were collected from KnowBe4’s global team of security awareness advocates who are experts with decades of experience in the cybersecurity field. For more information on KnowBe4’s team of experts, visit https://www.knowbe4.com/security-awareness-training-advocates .

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 44,000 organizations around the globe. Founded by IT and data security specialist, Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud, and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye